Adicet Bio Reports Q4 and Full-Year 2025 Financial Results: Major Clinical Milestones and Cash Update
Adicet Bio Reports Q4 and Full-Year 2025 Financial Results: Major Clinical Milestones and Cash Update
Key Highlights
- Strong Clinical Momentum: Accelerated enrollment in Phase 1 autoimmune program for prulacabtagene leucel (prula-cel), with two major clinical updates planned for 2026.
- FDA Regulatory Alignment: Achieved regulatory clearance for outpatient dosing of prula-cel in lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients, potentially increasing trial accessibility and reducing costs.
- Pivotal Trial Timeline: Plans to initiate pivotal study for prula-cel in LN or LN and SLE patients in 2H 2026, pending FDA discussions in Q2 2026.
- Pipeline Expansion: Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) expected in Q3 2026; Phase 1 enrollment to begin Q4 2026, subject to clearance.
- Capital Position: Ended 2025 with \$158.5 million in cash and equivalents after a \$74.8 million equity raise in October 2025, providing runway into 2H 2027.
- Financial Performance: Q4 net loss of \$30.5 million, full-year net loss of \$116.8 million, with R&D spend stable year-over-year and G&A expenses reduced.
In-Depth Operational Update
Autoimmune Diseases Program
- Phase 1 Prula-cel Study: The ongoing Phase 1 trial for prula-cel in multiple autoimmune indications (LN, SLE, SSc) is experiencing robust enrollment, attributed to high physician and patient interest. The company is set to provide a clinical update in 1H 2026, with another update planned for 2H 2026.
- Fast Track Designation: Prula-cel has FDA Fast Track status for relapsed/refractory Class III or IV LN, refractory SLE with extrarenal involvement, and systemic sclerosis (SSc), accelerating its development and review timelines.
- Outpatient Dosing Approval: In November 2025, Adicet reached FDA alignment to allow outpatient dosing for LN and SLE patients. This regulatory shift could streamline trial operations, lower costs, and enhance patient recruitment, which can be highly price-sensitive for investors.
- Upcoming Pivotal Study: FDA meetings in Q2 2026 will guide pivotal trial design. If cleared, Adicet plans to launch a pivotal trial for LN or LN and SLE in 2H 2026, setting the stage for a potential future regulatory submission and commercialization.
- Rheumatoid Arthritis (RA) Expansion: In October 2025, the first patient was dosed in a Phase 1 study for treatment-refractory RA, assessing two lymphodepletion regimens. Safety and disease activity data are expected in 2H 2026, expanding prula-cel’s market potential.
Solid Tumor Program
- ADI-212 for Prostate Cancer: Preclinical development on track, with a regulatory submission planned for Q3 2026. ADI-212 is a next-generation, gene-edited, armored cell therapy targeting PSMA, featuring a unique CAR binder, membrane-tethered IL-12, and CRISPR/Cas9-mediated MED12 disruption for enhanced potency in solid tumors.
- Phase 1 Timeline: Subject to regulatory clearance, Phase 1 enrollment for ADI-212 in mCRPC is expected to begin in Q4 2026.
- Scientific Validation: In October 2025, Adicet presented promising preclinical data at the Prostate Cancer Foundation Scientific Retreat, demonstrating functional enhancements and supporting their clinical rationale.
Financial Summary
- Q4 2025 Results: R&D expenses were \$25.0 million (up from \$23.3 million in Q4 2024), driven by a \$6.1 million increase in CRO/CDMO costs, offset by lower payroll and facility expenses. G&A was \$6.9 million (down from \$7.5 million), reflecting lower rent and professional fees, partially offset by higher stock-based compensation.
- Net Loss: Q4 net loss was \$30.5 million (\$2.94 per share), compared to \$28.7 million (\$5.06 per share) in Q4 2024. Full-year net loss was \$116.8 million (\$16.95 per share), nearly flat versus \$117.1 million (\$21.33 per share) in 2024, with stock-based compensation declining from \$22.2 million to \$14.3 million.
- Cash Position: Cash, cash equivalents, and short-term investments stood at \$158.5 million as of December 31, 2025, versus \$176.3 million a year prior. The October 2025 equity raise of \$74.8 million notably strengthened the balance sheet. The company anticipates current resources will fund operations into the second half of 2027.
Shareholder Considerations & Price-Sensitive Information
- Regulatory and Clinical Milestones: The achievement of FDA alignment for outpatient dosing and the timeline for pivotal trial initiation in autoimmune diseases are significant catalysts and may be material to share value.
- Pipeline Progress: The advancement of ADI-212 into clinical development for mCRPC, if successful, would represent entry into a large oncology market and further diversify Adicet’s pipeline.
- Cash Runway: The company’s clear statement of cash sufficiency into the second half of 2027, post capital raise, reduces immediate financing overhang concerns and supports continued R&D investment.
- Upcoming Clinical Readouts: Multiple data updates for prula-cel in 2026, including expansion into RA, present potential inflection points for valuation based on clinical outcomes.
- Operational Leverage: Despite continued losses, Adicet has managed to reduce G&A expenses and maintain R&D investment, signaling prudent expense control amid a focused clinical push.
About Adicet Bio
Adicet Bio is a clinical-stage biotech developing “off-the-shelf” allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, leveraging proprietary CAR engineering for enhanced patient outcomes.
Investor Contacts
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. Investors should review Adicet Bio’s filings with the SEC and consult their financial advisor before making investment decisions.
View Adicet Bio, Inc. Historical chart here
